CELZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CELZ is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading in a weak technical position, there is no Intellectia buy signal today, and the recent news flow is capital-raise driven rather than business-strength driven. For an impatient investor who does not want to wait for a better entry, this is still not an attractive immediate purchase.
The trend is bearish. MACD histogram is below zero at -0.0992 and still negatively contracting, showing momentum remains weak. RSI_6 at 35.185 is near oversold but not yet a strong reversal signal. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, which confirms the stock is below stronger trend levels. Price is around 1.215, well below the pivot level of 2.372, indicating the stock is still trading far from a constructive breakout zone. The short-term pattern forecast suggests possible near-term bounce potential, but the broader trend remains down.
Recent news includes a warrant exercise expected to generate about $4.5 million in gross proceeds, which improves cash resources. There was also a strong analyst endorsement in April 2026 from Roth Capital, who called Ultrasome 'highly positive' after pilot study results showing 93% of patients had clinically meaningful improvements in mobility and pain reduction without serious adverse events. Roth maintained a Buy rating with a $20 price target. The stock trend model also suggests a possible short-term rebound over the next day and month.
The recent corporate news is heavily dilution-focused, including a warrant exercise, new unregistered warrants, and a public offering of up to 3.05 million shares. The stock also had a meaningful decline earlier in the year, suggesting persistent market skepticism. There are no recent insider or hedge fund buying trends, and no recent congress trading data. Current price action remains weak despite the earlier clinical update.
No usable latest-quarter financial snapshot was provided, so I cannot assess the most recent quarter season or growth trends from the supplied data.
Wall Street sentiment is mixed-to-positive on the science but not on the stock action. Roth Capital’s Jonathan Aschoff rated CELZ Buy with a $20 target after highly positive Ultrasome pilot results, which is a strong bullish view on the company’s pipeline. However, the market response has been inconsistent, and the recent offering/dilution activity suggests pros see potential but also recognize financing needs and execution risk. Overall, analysts appear optimistic on the therapy pipeline, but current trading sentiment remains weak.
